| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acknowledgement of reviewers 2016
|
|
|
2017
|
81 |
2 |
p. 425
|
article
|
| 2 |
A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)
|
Kagawa, Shunsuke
|
|
2017
|
81 |
2 |
p. 387-392
|
article
|
| 3 |
A phase II trial of Ifosfamide combination with recommended supportive therapy for recurrent SCLC in second-line and heavily treated setting
|
Tanaka, Ichidai
|
|
2017
|
81 |
2 |
p. 339-345
|
article
|
| 4 |
A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin—integration of in vitro results, Phase I and Phase II data and model application for drug–drug interaction potential analysis
|
Hanke, Nina
|
|
2017
|
81 |
2 |
p. 291-304
|
article
|
| 5 |
A pilot study of daunorubicin-augmented hyper-CVAD induction chemotherapy for adults with acute lymphoblastic leukemia
|
Kim, Sung-Yong
|
|
2018
|
81 |
2 |
p. 393-398
|
article
|
| 6 |
B7-H3 in tumors: friend or foe for tumor immunity?
|
Li, Gen
|
|
2018
|
81 |
2 |
p. 245-253
|
article
|
| 7 |
Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study
|
Kataoka, Yuki
|
|
2017
|
81 |
2 |
p. 333-337
|
article
|
| 8 |
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men
|
Markus, Richard
|
|
2017
|
81 |
2 |
p. 419
|
article
|
| 9 |
Correction to: Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study
|
Jong, Jan de
|
|
2017
|
81 |
2 |
p. 423
|
article
|
| 10 |
Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
|
Chen, Shang-Chiung
|
|
2017
|
81 |
2 |
p. 421-422
|
article
|
| 11 |
CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
|
Zhou, Xinna
|
|
2017
|
81 |
2 |
p. 365-372
|
article
|
| 12 |
Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells
|
Fedorchuk, Olexandr
|
|
2017
|
81 |
2 |
p. 373-385
|
article
|
| 13 |
Influence of the ABCB1 polymorphisms on the response to Taxane-containing chemotherapy: a systematic review and meta-analysis
|
Jiang, Qi
|
|
2017
|
81 |
2 |
p. 315-323
|
article
|
| 14 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine
|
Phua, Lee Cheng
|
|
2017
|
81 |
2 |
p. 277-289
|
article
|
| 15 |
Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
|
Mistry, Hitesh B.
|
|
2017
|
81 |
2 |
p. 325-332
|
article
|
| 16 |
Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients
|
Schoch, L. K.
|
|
2017
|
81 |
2 |
p. 347-354
|
article
|
| 17 |
Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia
|
Völler, Swantje
|
|
2017
|
81 |
2 |
p. 305-314
|
article
|
| 18 |
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors
|
Chan, Emily
|
|
2017
|
81 |
2 |
p. 355-364
|
article
|
| 19 |
Positioning of proteasome inhibitors in therapy of solid malignancies
|
Roeten, Margot S. F.
|
|
2017
|
81 |
2 |
p. 227-243
|
article
|
| 20 |
Prediction of neutrophil reduction using plasma paclitaxel concentration after administration in patients with uterine, ovarian, or cervical cancers in an outpatient clinic
|
Ishikawa, Motoaki
|
|
2018
|
81 |
2 |
p. 399-411
|
article
|
| 21 |
Serum lipid and bone metabolism effects of Toremifene vs. Letrozole as adjuvant therapy for postmenopausal early breast cancer patients: results of a multicenter open randomized study
|
Shien, Tadahiko
|
|
2017
|
81 |
2 |
p. 269-275
|
article
|
| 22 |
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations
|
Liu, Xiaojun
|
|
2017
|
81 |
2 |
p. 255-267
|
article
|
| 23 |
The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer
|
Williams, Grant R.
|
|
2017
|
81 |
2 |
p. 413-417
|
article
|
Journal description